Product Information |
Product name |
Idebenone |
CAS No. |
58186-27-9 |
Molecular Formula |
C19H30O5 |
Molecular Weight |
338.444 |
Molecular Structure |
|
Quality Standard |
98.5% up by HPLC |
Appearance |
Orange to yellow crystalline powder |
COA |
ANALYSIS |
SPECIFICATION |
RESULTS |
Appearance |
Orange to yellow crystalline powder |
Conforms |
Melting range |
52-55℃ |
Conforms |
Loss on drying |
≤0.1% |
0.02% |
Residue on ignition |
≤0.1% |
0.02% |
Heavy metals |
≤10ppm |
Conforms |
Total impurities |
≤0.8% |
0.20% |
Assay (by HPLC) |
≥98.5% |
99.1% |
Residue solventies |
Hexane ≤ 0.029% |
0.006% |
Methanol ≤ 0.30% |
ND |
|
Toluene ≤ 0.89% |
0.0085% |
|
Assay((on dried bases) |
98.5% - 101.5% |
99.8% |
Conclusion |
The product meets the standard |
Usage |
What is Idebenone?
Idebenone (6-[10-hydroxydecil]-2,3-dymethoxy-5-methyl-1,4-benzoquinone) is a quinone
analogue, which is used in the treatment of several neurological disorders:
Friedreich ataxia (FRDA), mitochondrial encephalomyopathies, senile dementia,
and Huntington disease. Idebenone acts as an antioxidant through the action of
its quinone ring and diffuses more rapidly than ubiquinone across biological
membranes due to the modification of the composition and length of its side
chain. Besides being a potent antioxidant, idebenone also functions as an
electron transport carrier and has been reported to have various other effects,
including stimulation of nerve-growth factor production and blockade of
voltage-sensitive calcium channels. Idebenone is rapidly absorbed and has a
plasma half-life of 14.9 ± 0.7 h. It crosses the blood–brain barrier. Within 48
h, most of the compound is excreted as metabolites in urine and faeces.
*Products under the patent are only for R&D use